Skip to main content

Table 2 Immunogenicity to HPV Vaccine

From: Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years

HPV genotype

% Seropositivity *

95% CI §

cLIA GMT mMu/ml † (95% CI)

Anti-HPV 6

94.4

(72.7, 99.9)

427.0 (203.4, 903.4)

Anti-HPV 11

100

(81.5, 100)

596.7 (303.6, 1173.2)

Anti-HPV 16

100

(81.5, 100)

2263.2 (1019.3, 5024.8)

Anti-HPV 18

94.4

(72.7, 99.9)

331.9 (159.8, 689.2)

  1. *Seropositivity and anti-HPV values were determined in the 16 patients who completed the vaccine HPV series and had both pre- and post-vaccination serum available for HPV antibody measurement.
  2. § CI = Confidence Interval.
  3. †cLIA GMT mMu = Competitive Luminex immunoassay, Geometric Mean Titers measured in milli-Merck units.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096